undefined

Naveen Pemmaraju

MD from The University of Texas MD Anderson Cancer Center, Houston, TX, providing expertise on BPDCN treatment strategies and ongoing trials.

Top 3 podcasts with Naveen Pemmaraju

Ranked by the Snipd community
undefined
Dec 18, 2024 • 29min

Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents

In this insightful discussion, Dr. Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center shares his expertise on treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). He dives into the challenges of managing this rare cancer and reviews current therapies like tagraxofusp. The conversation also covers patient eligibility, the role of stem cell transplants, and emerging treatments targeting CD123. Dr. Pemmaraju highlights ongoing clinical trials that promise to advance treatment strategies and improve outcomes for BPDCN patients.
undefined
Jul 29, 2024 • 16min

Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials

Naveen Pemmaraju, a medical doctor at The University of Texas MD Anderson Cancer Center, joins the discussion on unmet treatment needs in myelofibrosis (MF). They explore the complexities of managing prefibrotic MF and the challenges of thrombocytopenia. Insights into novel therapies like megakaryocyte-focused treatments and the importance of early intervention are highlighted. The conversation emphasizes patient participation in choosing therapies and the potential of innovative approaches like immune vaccines to improve outcomes.
undefined
Jun 3, 2024 • 35min

BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients

Hematologist Naveen Pemmaraju discusses BPDCN treatment, focusing on CD123-targeting agents like Tagraxofusp. The guests emphasize the importance of early diagnosis, CNS involvement, and tailored strategies for treating adolescents and young adults with this aggressive disease.